Lynk Pharmaceuticals Files for Hong Kong IPO – Autoimmune Pipeline Led by JAK Inhibitors and Novel Protein Degraders
Lynk Pharmaceuticals Co., Ltd. announced it has published its prospectus and formally applied for listing...
Bayer Secures FDA Approval for Ambelvist – Novel High-Relaxivity MRI Contrast Agent with Lower Gadolinium Dose
Bayer AG (ETR: BAYN) announced that the U.S. Food and Drug Administration (FDA) has granted...
Shanghai Leadingtac Secures NMPA Approval for LT-010391 – China’s First Clinical-Stage Oral KRAS-G12D Degrader
Shanghai Leadingtac Pharmaceutical Co., Ltd. announced that China’s National Medical Products Administration (NMPA) has granted...
Fosun Pharma Secures NMPA Approval for Fumaining in Pediatric Langerhans Cell Histiocytosis – Expands MEK Inhibitor Franchise
Fosun Pharmaceutical (Group) Co., Ltd. (SHA: 600196; HKG: 2196) announced that China’s National Medical Products...
TriApex Laboratories Files for Hong Kong IPO – Next-Generation CRO with 240+ NMPA Approvals
TriApex Laboratories Co., Ltd. announced it has published its prospectus and formally applied for listing...
Ningbo Sanxing Medical Electric Files HKEX Prospectus with Dual Business Model in Power Equipment and Rehabilitation Services
Ningbo Sanxing Medical Electric Co., Ltd. announced it has filed its prospectus for listing on...
Gritpharma Secures NMPA Approval for Doxylamine as China’s First Novel Short-Term Insomnia Treatment
Nanjing Gritpharma Co., Ltd. announced it has received marketing approval from China’s National Medical Products...
Baheal Pharma Partners with Jinan Junxin Hospital to Launch ZAP-X Precision Radiosurgery Center
Baheal Pharma Group (SHE: 301015) announced a strategic partnership with Jinan Junxin Cancer Hospital to...
Lannacheng Biotechnology Files HKEX Prospectus with 13-Candidate Radiopharmaceutical Pipeline
Yantai Lannacheng Biotechnology Co., Ltd. announced it has filed its prospectus for listing on the...
Harbour BioMed Wins $20.2 Million Patent Verdict Against Amgen in Delaware Court
Harbour BioMed (HKG: 2142) announced that a jury in the U.S. District Court for the...
Sichuan Biokin’s Iza-Bren Becomes World’s First EGFR×HER3 Bispecific ADC with NDA Accepted by China’s NMPA
Sichuan Biokin Pharmaceutical Co., Ltd. (SHA: 688506) announced that the new drug application (NDA) for...
SSY Group Secures Exclusive China License for OPT101, Novel Peritoneal Dialysis Therapy from Opterion Health
SSY Group Limited (HKG: 2005) announced it has entered into a letter of intent with...
Simcere Pharmaceutical Partners with Stanford University to Develop First-in-Class IPF Therapy
Simcere Pharmaceutical Group (HKG: 2096) announced a collaborative research agreement with Stanford University School of...
Novo Nordisk to Fully Launch Sogroya in China This Summer for Pediatric Growth Hormone Deficiency
Novo Nordisk (NYSE: NVO) announced that its long-acting growth hormone injection Sogroya (somapacitan) will be...
Medtronic Completes $550 Million Acquisition of Scientia Vascular to Strengthen Neurovascular Portfolio
Medtronic (NYSE: MDT) announced on June 12, 2026 the completion of its acquisition of Scientia...
Sanofi’s Tzield Receives FDA Approval to Preserve Insulin Production in Recently Diagnosed Type 1 Diabetes
Sanofi (NASDAQ: SNY) announced that the U.S. Food and Drug Administration (FDA) has granted accelerated...
Roche’s VENTANA PTEN Assay Receives FDA Approval as First Companion Diagnostic for AstraZeneca’s Truqap in Prostate Cancer
Roche Holding AG (SWX: ROP, OTCMKTS: RHHBY) announced that the VENTANA PTEN (SP218) RxDx Assay...
Jazz Pharmaceuticals Reports Phase 3 LAGOON Trial Misses Primary Endpoint for Zepzelca in Relapsed Small Cell Lung Cancer
Jazz Pharmaceuticals (NASDAQ: JAZZ) announced on June 12, 2026 that the Phase 3 LAGOON trial,...
AstraZeneca’s Truqap Receives FDA Approval as First Targeted Therapy for PTEN-Deficient Prostate Cancer
AstraZeneca plc (NYSE: AZN) announced that the U.S. Food and Drug Administration (FDA) has approved...
Micot Pharmaceutical Successfully Lists on Hong Kong Stock Exchange with HK$1.22 Billion IPO
Shaanxi Micot Pharmaceutical Technology Co., Ltd. (HKG: 2355) announced its successful listing on the Hong...